About Opexa Therapeutics
Opexa Therapeutics is a Healthcare company based in The Woodlands (United States) founded in 2004, and was acquired by Acer Therapeutics in July 2017. Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis. Opexa Therapeutics has raised $5.84 million across 3 funding rounds from investors including Acer Therapeutics. The company has 9 employees. Opexa Therapeutics offers products and services including Tcelna and OPX-212. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Opexa Therapeutics, Inc. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Opexa Therapeutics was established in 2004 through the merger of PharmaFrontiers and Opexa Pharmaceuticals. Patient-specific immunotherapies are developed by the company for multiple sclerosis treatment within the biotechnology sector. The leading candidate, Tcelna, is designed for Secondary Progressive Multiple Sclerosis. Operations are conducted from The Woodlands, United States, focusing on autoimmune disease applications.
- Headquarters The Woodlands, United States
- Employees 9
- Stage Acquired
- SectorsHealthcare
- Website opexatherapeutics.com
- Social LinkedIn X Facebook
- Acquired by Acer Therapeutics (Jul 2017)
- Legal Name Opexa Therapeutics, Inc.
- Annual Revenue$2.91 M (USD)14as on Dec 31, 2016
- Net Profit-$7.98 M (USD)34as on Dec 31, 2016
- EBITDA-$7.75 M (USD)34as on Dec 31, 2016
- Total Equity Funding$5.84M (USD)
in 3 rounds
- Latest Funding Round$650K (USD), Series A
Feb 2013
- Investors
- Employee Count9
- Acquired byAcer Therapeutics
(Jul 2017)
Products & Services of Opexa Therapeutics
Opexa Therapeutics offers a comprehensive portfolio of products and services, including Tcelna and OPX-212.
Personalized T-cell therapy for multiple sclerosis treatment
Autologous T-cell therapy for neuromyelitis optica
Funding Insights of Opexa Therapeutics
Opexa Therapeutics has successfully raised a total of $5.84M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $650 thousand completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.84M
- Total Rounds 3
- Last Round Series A β $650,000
- First Round $1.1M
(Apr 2009)
All 3 funding rounds of Opexa Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2013 | $650,000 | Series A | β | β | β |
| Jul 2012 | $4.09M | Series A | β | β | β |
| Apr 2009 | $1.1M | Seed | β | β | β |
1 investors in total: 1 institutional.
Investors in Opexa Therapeutics
Opexa Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Acer Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Treatments for ultra-rare diseases like vEDS and MSUD are developed. | 1991 | acertx.com | Cambridge, United States |
Investor details for Opexa Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Opexa Therapeutics
4 dated milestones of Opexa Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Opexa Therapeutics is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Series A, of $650K.
- Exit Acquired by Acer Therapeutics.
Competitors of Opexa Therapeutics
Opexa Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Opexa Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Opexa Therapeutics
Websites that share an audience with Opexa Therapeutics (opexatherapeutics.com).
Websites whose visitors overlap most with Opexa Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
ir.kkr.com | ir.kkr.com | 100% | β | ||
| worldtopinvestor.com | 100% | #13,551,810 | View details | ||
| amttraining.com | 100% | 3.3K | #5,661,489 | View details | |
| iif.com | 100% | 83.7K | #494,500 | View details | |
store.mortgagebankers.org | store.mortgagebankers.org | 61% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 6 similar websites and full traffic analytics for Opexa Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Opexa Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Opexa Therapeutics
Complete news archive for Opexa Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Opexa Therapeutics
Opexa Therapeutics was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Opexa Therapeutics is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Opexa Therapeutics is a funded company, having raised a total of $5.84M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.1M, raised on Apr 2009.
Opexa Therapeutics has 9 employees.
Annual revenue of Opexa Therapeutics is $2.91M as on Dec 31, 2016.
Opexa Therapeutics was established in 2004 through the merger of PharmaFrontiers and Opexa Pharmaceuticals. Patient-specific immunotherapies are developed by the company for multiple sclerosis treatment within the biotechnology sector. The leading candidate, Tcelna, is designed for Secondary Progressive Multiple Sclerosis. Operations are conducted from The Woodlands, United States, focusing on autoimmune disease applications.
Opexa Therapeutics's top competitors include ADMA Biologics, Kymeratx and Biogen.
Opexa Therapeutics offers Tcelna and OPX-212.
Opexa Therapeutics has 1 investor. Key investors include Acer Therapeutics.
Opexa Therapeutics operates through Opexa Therapeutics, Inc..
Yes. Opexa Therapeutics was acquired by Acer Therapeutics in July 2017.

